Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy

Central Serous Chorioretinopathy Clinical Trial

Official title:

A Randomized Controlled Study of Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05687422
• Other study ID #: 2021-I2M-C&T-B-093
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 1, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2023
• Source: Beijing Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Central serous chorioretinopathy (CSC) is a common eye disease mainly involving the macular area, causing central visual acuity loss. Recently, subthreshold micropulse laser used in treating chronic CSC is proved to be safe and effective. However, some studies indicate that it's less effective than half dose photodynamic therapy (PDT). Certain physicians, including us, think that this may be related to micropulse laser parameters. Thus we need to explore better laser patterns to replace PDT in treating chronic CSC. The aim of this study is to compare the treatment effect of two different patterns of laser parameters (small and regular spot diameter) in treating chronic CSC. In this randomized, double blinded, controlled trial, by comparing the subretinal fluid regression ratio, central retinal thickness, macular microvisual field, macular vascular density, chroidal volume changes and visual acuity of two groups 6 months after micropulse laser treatment, we aim to evaluate the safety and efficacy of refined micropulse laser in treating chronic CSC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Patients age range 18-50 years

• Patients diagnosed with chronic Central serous chorioretinopathy

• Patients have signed informed consent

Exclusion Criteria:

• A history of other fundus diseases or refractive media opacity

• Patients have underwent other treatment methods for chronic Central serous chorioretinopathy

• Diopter>-6D

• A history of system diseases such as hypertension or diabetes

• A history of using local or systemic corticosteroids

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

Intervention

Procedure:
• 100µm laser spot diameter micropulse laser
100µm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
• 200µm laser spot diameter micropulse laser
200µm laser spot diameter micropulse laser at baseline, then follow-up for 6 months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Subretinal fluid regression ratio	Comparing the subretinal fluid regression ratio of two groups at 6 months follow-up	6 months
Primary	Central retinal thickness changes	Comparing the central retinal thickness changes of two groups at 6 months	6 months